$CBUS
Cibus, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021025006 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $4.400M $2.377M
YoY Change 85.11% 1414.01%
Cost Of Revenue $6.750M $3.884M
YoY Change 73.79% 11323.53%
Gross Profit -$2.340M -$1.507M
YoY Change 55.28% -1325.2%
Gross Profit Margin -53.18% -63.4%
Selling, General & Admin $4.290M $6.300M
YoY Change -31.9% 20.21%
% of Gross Profit
Research & Development $3.050M $2.787M
YoY Change 9.44% 25.6%
% of Gross Profit
Depreciation & Amortization $585.0K $452.0K
YoY Change 29.42% 32.16%
% of Gross Profit
Operating Expenses $7.338M $9.147M
YoY Change -19.78% 19.63%
Operating Profit -$9.681M -$10.65M
YoY Change -9.13% 41.62%
Interest Expense $360.0K $372.0K
YoY Change -3.23% 0.54%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$11.00K
YoY Change -90.91%
Pretax Income -$10.03M -$11.06M
YoY Change -9.36% 50.01%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.03M -$11.06M
YoY Change -9.36% 50.01%
Net Earnings / Revenue -227.91% -465.42%
Basic Earnings Per Share
Diluted Earnings Per Share -$270.1K -$335.3K
COMMON SHARES
Basic Shares Outstanding 32.99M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.40M $46.00M
YoY Change -57.83% -45.37%
Cash & Equivalents $16.39M $7.385M
Short-Term Investments $3.000M $38.60M
Other Short-Term Assets $3.700M $2.000M
YoY Change 85.0% -9.09%
Inventory $4.500M $3.198M
Prepaid Expenses
Receivables $1.354M $841.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $29.10M $52.03M
YoY Change -44.07% -40.21%
LONG-TERM ASSETS
Property, Plant & Equipment $22.50M $22.90M
YoY Change -1.76% 4.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $441.0K
YoY Change 81.41% -34.57%
Total Long-Term Assets $23.30M $24.39M
YoY Change -4.46% 3.13%
TOTAL ASSETS
Total Short-Term Assets $29.10M $52.03M
Total Long-Term Assets $23.30M $24.39M
Total Assets $52.40M $76.42M
YoY Change -31.43% -30.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.000M $1.085M
YoY Change -7.83% 49.86%
Accrued Expenses $4.800M $2.093M
YoY Change 129.34% 30.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $400.0K $400.0K
YoY Change 0.0% 33.33%
Total Short-Term Liabilities $6.300M $5.550M
YoY Change 13.51% 19.35%
LONG-TERM LIABILITIES
Long-Term Debt $19.30M $18.20M
YoY Change 6.04% 0.0%
Other Long-Term Liabilities $1.200M $141.0K
YoY Change 751.06% -9.62%
Total Long-Term Liabilities $20.50M $141.0K
YoY Change 14439.01% -9.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.300M $5.550M
Total Long-Term Liabilities $20.50M $141.0K
Total Liabilities $26.80M $23.89M
YoY Change 12.2% 3.99%
SHAREHOLDERS EQUITY
Retained Earnings -$133.1M
YoY Change 48.21%
Common Stock $186.9M
YoY Change 5.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.61M $52.54M
YoY Change
Total Liabilities & Shareholders Equity $52.40M $76.42M
YoY Change -31.43% -30.95%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$10.03M -$11.06M
YoY Change -9.36% 50.01%
Depreciation, Depletion And Amortization $585.0K $452.0K
YoY Change 29.42% 32.16%
Cash From Operating Activities -$9.417M -$12.24M
YoY Change -23.05% 31.93%
INVESTING ACTIVITIES
Capital Expenditures $269.0K $317.0K
YoY Change -15.14% -8.38%
Acquisitions
YoY Change
Other Investing Activities $8.650M -$38.62M
YoY Change -122.4%
Cash From Investing Activities $8.384M -$38.94M
YoY Change -121.53% 11153.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 120.0K -45.00K
YoY Change -366.67% -168.18%
NET CHANGE
Cash From Operating Activities -9.417M -12.24M
Cash From Investing Activities 8.384M -38.94M
Cash From Financing Activities 120.0K -45.00K
Net Change In Cash -913.0K -51.22M
YoY Change -98.22% 436.0%
FREE CASH FLOW
Cash From Operating Activities -$9.417M -$12.24M
Capital Expenditures $269.0K $317.0K
Free Cash Flow -$9.686M -$12.56M
YoY Change -22.85% 30.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
11698000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1518000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2020Q4 us-gaap Liabilities
Liabilities
26452000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204807000
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1043000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166893000
CY2021Q1 clxt Management Fees And Royalties
ManagementFeesAndRoyalties
30000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7338000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
9147000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9681000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10654000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-346000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-398000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10028000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11063000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10028000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-11063000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37136338
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32988141
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5013780
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5328268
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
36875000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
208000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25605000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-11063000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-180000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
52536000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10028000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-11063000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
585000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
452000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
-1450000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1271000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3533000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-281000
CY2021Q1 clxt Increase Decrease In Due To From Related Parties Current
IncreaseDecreaseInDueToFromRelatedPartiesCurrent
-652000
CY2020Q1 clxt Increase Decrease In Due To From Related Parties Current
IncreaseDecreaseInDueToFromRelatedPartiesCurrent
-430000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3149000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
604000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-583000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
786000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
30000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8000
CY2021Q1 clxt Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
167000
CY2020Q1 clxt Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
-451000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-186000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-818000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1100000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-9000
CY2021Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-50000
CY2020Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
89000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9417000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12238000
CY2021Q1 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-8653000
CY2020Q1 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
38620000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
269000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
317000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8384000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38937000
CY2021Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
88000
CY2020Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
45000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-45000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-913000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51220000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18289000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60038000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17376000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8818000
CY2020Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
12165000
CY2021Q1 clxt Finance Lease Obligations Fair Value Disclosure
FinanceLeaseObligationsFairValueDisclosure
15100000
CY2020Q4 clxt Finance Lease Obligations Fair Value Disclosure
FinanceLeaseObligationsFairValueDisclosure
15200000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1902128
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2347663
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.15
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4621173
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.30
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
270800
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.07
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56372
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.71
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
456450
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.03
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2369997
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.38
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4379151
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.27
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
331000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6900000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1354000
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4317000
CY2021Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
13000
CY2020Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
24000
CY2021Q1 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
11700000
CY2021Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1107000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4887000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-1450000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1271000
CY2021Q1 us-gaap Interest Expense
InterestExpense
360000
CY2020Q1 us-gaap Interest Expense
InterestExpense
372000
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
14000
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-26000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-346000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-398000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16386000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7385000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
393000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
388000
CY2021Q1 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
597000
CY2020Q1 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1045000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17376000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8818000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
3045000
CY2020Q1 us-gaap Short Term Investments
ShortTermInvestments
38620000

Files In Submission

Name View Source Status
0001564590-21-025006-index-headers.html Edgar Link pending
0001564590-21-025006-index.html Edgar Link pending
0001564590-21-025006.txt Edgar Link pending
0001564590-21-025006-xbrl.zip Edgar Link pending
clxt-10q_20210331.htm Edgar Link pending
clxt-10q_20210331_htm.xml Edgar Link completed
clxt-20210331.xsd Edgar Link pending
clxt-20210331_cal.xml Edgar Link unprocessable
clxt-20210331_def.xml Edgar Link unprocessable
clxt-20210331_lab.xml Edgar Link unprocessable
clxt-20210331_pre.xml Edgar Link unprocessable
clxt-ex103_108.htm Edgar Link pending
clxt-ex104_106.htm Edgar Link pending
clxt-ex105_107.htm Edgar Link pending
clxt-ex311_105.htm Edgar Link pending
clxt-ex312_102.htm Edgar Link pending
clxt-ex32_104.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
godlgfhwlvva000001.jpg Edgar Link pending
gufyrvlzahhr000001.jpg Edgar Link pending
gznrnccbndpi000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending